---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059457"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:57:30.464563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q1 product sales up 14% to $9.0M; gross margin expands to 76%

## Summary
- Product sales $9.0M, +14% YoY from $7.9M and +22% sequentially from Q4 2023 ($7.3M).
- Product gross margins 76% (excl. $304K one-time adjustment), up from 68% in Q1 2023.
- Total revenue $9.8M (+4% YoY) as grant income fell 48% to $0.8M on completion of prior grants.
- Plans FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024; STAR-T data presented at AATS.
- Cash $10.1M (incl. $1.5M restricted) expected to fund operations into Q4 2024; seeking non-dilutive financing.

## SEC filing metadata
- accession: 0001104659-24-059457
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/0001104659-24-059457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/tm2414028d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059457
- JSON: https://secwatch.observer/filing/0001104659-24-059457.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059457.txt

## Key facts
- Earnings Releases
  Cytosorbents Corp reported the quarter ended March 31, 2024 results: revenue $9.8 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $9.8 million
  - Result: reported results
  source text: $7.9 million in Q1 2023, an increase of 14%, and up 22% sequentially from $7.3 million in Q4 2023 · Total revenue, including product sales and grant income, for Q1 2024 was $9.8 million, an increase of 4% compared to $9.4 million in Q1 2023 · Q1 2024 product gross margins increased to approximately 76%, (excluding the impact of a one-time,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465924059457/0001104659-24-059457-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.